KR102741265B1 - 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 - Google Patents
미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 Download PDFInfo
- Publication number
- KR102741265B1 KR102741265B1 KR1020207018744A KR20207018744A KR102741265B1 KR 102741265 B1 KR102741265 B1 KR 102741265B1 KR 1020207018744 A KR1020207018744 A KR 1020207018744A KR 20207018744 A KR20207018744 A KR 20207018744A KR 102741265 B1 KR102741265 B1 KR 102741265B1
- Authority
- KR
- South Korea
- Prior art keywords
- human
- akkermansia
- article
- abundance
- hmo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700680 | 2017-11-30 | ||
| DKPA201700680 | 2017-11-30 | ||
| DKPA201700690 | 2017-12-05 | ||
| DKPA201700690 | 2017-12-05 | ||
| PCT/IB2018/059501 WO2019106620A1 (en) | 2017-11-30 | 2018-11-30 | Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200091438A KR20200091438A (ko) | 2020-07-30 |
| KR102741265B1 true KR102741265B1 (ko) | 2024-12-11 |
Family
ID=66664406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207018744A Active KR102741265B1 (ko) | 2017-11-30 | 2018-11-30 | 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200323921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3716983A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021504420A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102741265B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111683665A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020010843A2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019106620A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234992B2 (en) * | 2018-02-28 | 2022-02-01 | The Regents Of The University Of California | Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides |
| JP2022513524A (ja) | 2018-12-19 | 2022-02-08 | グリコム・アクティーゼルスカブ | 低fodmap食を使用してヒトを治療するための組成物および方法 |
| US20220054515A1 (en) * | 2018-12-21 | 2022-02-24 | Glycom A/S | Composition and method for promoting intestinal barrier healing |
| EP3980025A4 (en) * | 2019-06-05 | 2023-06-14 | Glycom A/S | HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-CELIAC GLUTEN AND/OR WHEAT SENSITIVITY |
| AU2020354581A1 (en) * | 2019-09-24 | 2022-03-03 | Prolacta Bioscience, Inc. | Compositions and methods for treatment of inflammatory and immune diseases |
| WO2021094993A1 (en) * | 2019-11-14 | 2021-05-20 | Glycom A/S | Synthetic composition for balancing the bile acid profile in the intestine |
| US11331329B2 (en) | 2020-05-13 | 2022-05-17 | Glycosyn LLC | Fucosylated oligosaccharides for prevention of coronavirus infection |
| EP4149482A4 (en) | 2020-05-13 | 2024-05-22 | Glycosyn LLC | 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION |
| US11896603B2 (en) * | 2020-06-12 | 2024-02-13 | The Regents Of The University Of California | Oligosaccharide as therapeutic agent for alcohol associated liver disease |
| JP2023536090A (ja) * | 2020-07-31 | 2023-08-23 | アボット・ラボラトリーズ | 脂肪肝疾患を予防、低減または遅延させる方法 |
| WO2022117829A1 (en) * | 2020-12-04 | 2022-06-09 | Société des Produits Nestlé S.A. | Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration |
| KR102456307B1 (ko) * | 2021-11-10 | 2022-10-19 | 충남대학교산학협력단 | 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물 |
| JP2023096870A (ja) * | 2021-12-27 | 2023-07-07 | 株式会社明治 | アッカーマンシア属細菌の増殖促進剤 |
| US20260165955A1 (en) | 2022-03-18 | 2026-06-18 | Meiji Co., Ltd. | Composition for controlling growth of bacteria of the genus collinsella and use thereof |
| CN115089596A (zh) * | 2022-06-20 | 2022-09-23 | 自然资源部第三海洋研究所 | 新琼寡糖用于制备治疗抑郁症产品的新用途 |
| WO2024126578A1 (en) * | 2022-12-13 | 2024-06-20 | Dsm Ip Assets B.V. | Synthetic composition comprising a human milk oligosaccharide for microbiota modulation |
| CN119138609B (zh) * | 2024-11-19 | 2025-02-25 | 飞鹤(吉林)乳品有限公司 | 母乳低聚糖改善母婴肠道菌群的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017046711A1 (en) * | 2015-09-14 | 2017-03-23 | Glycom A/S | Synthetic composition for microbiota modulation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005055944A2 (en) * | 2003-12-05 | 2005-06-23 | Cincinnati Children's Hospital Medical Center | Oligosaccharide compositions and use thereof in the treatment of infection |
| JP2012532195A (ja) * | 2009-07-06 | 2012-12-13 | チルドレンズ ホスピタル メディカル センター | 乳オリゴ糖による炎症の阻害 |
| EP2439264B1 (en) * | 2010-10-11 | 2015-06-03 | Jennewein Biotechnologie GmbH | Novel fucosyltransferases and their applications |
| MX356184B (es) * | 2010-12-31 | 2018-05-17 | Abbott Lab | Fórmulación pediátrica sintética que comprende un probiótico. |
| AU2012215042B2 (en) * | 2011-02-10 | 2016-01-14 | Société des Produits Nestlé S.A. | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
| US20140187474A1 (en) * | 2011-02-16 | 2014-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic use of mucin glycans |
| JP6129821B2 (ja) * | 2011-05-13 | 2017-05-17 | グリコシン リミテッド ライアビリティー カンパニー | プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用 |
| NL2007268C2 (en) * | 2011-08-16 | 2013-02-19 | Friesland Brands Bv | Nutritional compositions comprising human milk oligosaccharides and uses thereof. |
| US10639319B2 (en) * | 2011-08-29 | 2020-05-05 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| MX2014012362A (es) * | 2012-04-13 | 2015-05-07 | Trustees Boston College | Composición prebiótica y métodos de uso. |
| EP2842560A4 (en) * | 2012-04-23 | 2015-12-02 | Univ Kyoto | COMPOSITION TO PROMOTE THE GROWTH OF BIFIDOBAKTERIA |
| WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| GB201312713D0 (en) * | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
| WO2014201037A2 (en) * | 2013-06-10 | 2014-12-18 | New York University | Methods for manipulating immune responses by altering microbiota |
| CN107108677B (zh) * | 2014-10-24 | 2020-08-07 | 格礼卡姆股份公司 | Hmo的混合物 |
| US20170258820A1 (en) * | 2014-10-29 | 2017-09-14 | Glycom A/S | Synthetic composition and method for promoting mucosal healing |
| US20160287637A1 (en) * | 2014-12-08 | 2016-10-06 | Glycom A/S | Synthetic composition and method for modulating emotion and mood disorders |
| US10881674B2 (en) * | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| MX378680B (es) * | 2015-03-05 | 2025-03-11 | Soc Des Produits Nestle S A Star | Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños. |
| US10537597B2 (en) * | 2015-10-05 | 2020-01-21 | Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos | Use of Akkermansia muciniphila for treating inflammatory conditions |
| US10780103B2 (en) * | 2015-10-28 | 2020-09-22 | Glycom A/S | Synthetic composition and method for modulating emotion and mood disorders |
| CN108471793A (zh) * | 2016-01-26 | 2018-08-31 | 雀巢产品技术援助有限公司 | 用于婴儿或幼儿以预防或治疗变态反应的包含人乳低聚糖的组合物 |
| EP3589139A4 (en) * | 2017-03-01 | 2020-12-23 | Glycom A/S | SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION |
| WO2018207110A1 (en) * | 2017-05-09 | 2018-11-15 | Glycom A/S | Synthetic composition for microbiota modulation |
| US20180333426A1 (en) * | 2017-05-17 | 2018-11-22 | Mead Johnson Nutrition Company | Nutritional composition with human milk oligosaccharides and uses thereof |
| US11541068B2 (en) * | 2017-05-24 | 2023-01-03 | Glycom A/S | HMO compositions and methods for reducing autism spectrum disorder symptoms |
| EP3743078A4 (en) * | 2017-12-22 | 2022-01-19 | Glycom A/S | COMPOSITION WITH HMOs TO PREVENT OR REDUCE NOCICEPTION |
-
2018
- 2018-11-30 EP EP18882623.4A patent/EP3716983A4/en active Pending
- 2018-11-30 JP JP2020529534A patent/JP2021504420A/ja active Pending
- 2018-11-30 BR BR112020010843-0A patent/BR112020010843A2/pt unknown
- 2018-11-30 CN CN201880088085.XA patent/CN111683665A/zh active Pending
- 2018-11-30 WO PCT/IB2018/059501 patent/WO2019106620A1/en not_active Ceased
- 2018-11-30 KR KR1020207018744A patent/KR102741265B1/ko active Active
- 2018-11-30 US US16/768,414 patent/US20200323921A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017046711A1 (en) * | 2015-09-14 | 2017-03-23 | Glycom A/S | Synthetic composition for microbiota modulation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021504420A (ja) | 2021-02-15 |
| US20200323921A1 (en) | 2020-10-15 |
| WO2019106620A1 (en) | 2019-06-06 |
| CN111683665A (zh) | 2020-09-18 |
| KR20200091438A (ko) | 2020-07-30 |
| EP3716983A1 (en) | 2020-10-07 |
| EP3716983A4 (en) | 2022-03-02 |
| BR112020010843A2 (pt) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11696921B2 (en) | Synthetic composition for microbiota modulation | |
| US11529365B2 (en) | Synthetic composition for microbiota modulation | |
| US20200323921A1 (en) | Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation | |
| US11291677B2 (en) | Synthetic composition for microbiota modulation | |
| US11278558B2 (en) | Synthetic composition for microbiota modulation | |
| US11998558B2 (en) | Synthetic composition for treating antibiotic associated complications | |
| US11541067B2 (en) | HMO compositions and methods for reducing detrimental proteolytic metabolites | |
| JP2017533915A (ja) | 過敏性腸症候群の治療のための合成組成物および方法 | |
| US20220378809A1 (en) | Synthetic composition for balancing the bile acid profile in the intestine | |
| EP3630124A1 (en) | Synthetic composition comprising oligosaccharides and its use in medical treatment. | |
| US11554131B2 (en) | Mixture of HMOs for treating autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |